uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.517 | Q34 | What are the names of the genes that are targeted by the drug Esketamine Hydrochloride in the treatment of unipolar depression? | In the context of unipolar depression, the drug Esketamine Hydrochloride targets the gene glutamate ionotropic receptor NMDA type subunit 1, glutamate ionotropic receptor NMDA type subunit 2A, glutamate ionotropic receptor NMDA type subunit 2B, glutamate ionotropic receptor NMDA type subunit 2D, glutamate ionotropic receptor NMDA type subunit 3B, glutamate ionotropic receptor NMDA type subunit 2C and glutamate ionotropic receptor NMDA type subunit 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%esketamine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%esketamine hydrochloride%" OR LOWER(syns_list) LIKE "%esketamine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_454753', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454765', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454769', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454773', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454781', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454785', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454789', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454797', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454801', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454805', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454809', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454817', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454821', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454825', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454829', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454833', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454837', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454841', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454845', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454849', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454853', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454861', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454865', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454869', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454873', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454877', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454885', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454889', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454893', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454897', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454901', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454905', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454909', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454913', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454917', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454921', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454925', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454929', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454933', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454937', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454941', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454945', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454949', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454953', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454957', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454961', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454965', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454969', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454973', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454977', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454981', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_454857', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_454793', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454761', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454745', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454737', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454733', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454881', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_454813', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_454777', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_454757', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454749', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454741', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_list': "['Spravato']", 'syns_list': "['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-Ketamine hydrochloride, s-', 'Ketanest s']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.83 | Q34 | What are the names of the genes that are targeted by the drug Bromocriptine Mesylate in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Bromocriptine Mesylate targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_list) LIKE "%bromocriptine mesylate%" OR LOWER(syns_list) LIKE "%bromocriptine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201379', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201400', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201407', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201414', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201428', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201435', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201442', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201456', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201463', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201470', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201477', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201491', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201498', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201505', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201512', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201519', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201526', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201533', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201540', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201547', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201554', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201568', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201575', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201582', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201589', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201596', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201610', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201617', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201624', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201631', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201638', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201645', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201652', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201659', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201666', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201673', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201680', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201687', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201694', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201701', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201708', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201715', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201722', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201729', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201736', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201743', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201750', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201757', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201764', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201771', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201778', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201792', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201799', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201806', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201813', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201820', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201827', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201841', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201848', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201855', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201862', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201869', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201876', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201883', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201890', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201897', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201904', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201911', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201918', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201925', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201932', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201939', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201946', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201953', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201960', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201967', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201974', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201981', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201988', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201995', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202002', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202009', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202016', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202023', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202030', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202037', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201785', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201561', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201449', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201393', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201365', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201351', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201344', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201834', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201603', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201484', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201421', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201386', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201372', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201358', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1435 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of familial hypercholesterolemia? | In the context of familial hypercholesterolemia, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043740', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043782', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043796', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043810', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043838', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043852', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043866', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043894', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043908', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043922', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043936', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043964', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043978', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043992', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043880', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043768', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043712', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043684', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043670', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043950', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043824', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043754', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043726', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043698', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1935 | Q34 | What are the names of the genes that are targeted by the drug Belzutifan in the treatment of clear cell renal carcinoma? | In the context of clear cell renal carcinoma, the drug Belzutifan targets the gene endothelial PAS domain protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%clear cell renal carcinoma%" OR LOWER(efo_term) LIKE "%clear cell renal carcinoma%") AND (LOWER(drugName) LIKE "%belzutifan%" OR LOWER(tradeNames_list) LIKE "%belzutifan%" OR LOWER(syns_list) LIKE "%belzutifan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192110', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192118', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.382 | Q34 | What are the names of the genes that are targeted by the drug Mometasone Furoate in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Mometasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%mometasone furoate%" OR LOWER(tradeNames_list) LIKE "%mometasone furoate%" OR LOWER(syns_list) LIKE "%mometasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242036', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242114', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242140', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242166', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242218', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242088', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241984', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241932', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241906', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242192', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242062', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242010', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241958', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1489 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of juvenile idiopathic arthritis? | In the context of juvenile idiopathic arthritis, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile idiopathic arthritis%" OR LOWER(efo_term) LIKE "%juvenile idiopathic arthritis%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057590', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058073', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058234', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058395', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058717', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058878', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059039', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059361', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059522', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059683', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059844', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060166', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060327', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060488', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060649', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060810', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060971', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061132', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061293', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061454', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061615', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061937', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062098', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062259', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062420', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062581', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062903', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063064', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063225', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063386', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063547', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063708', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063869', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064030', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064191', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064352', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064513', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064674', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064835', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064996', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065157', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065318', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065479', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065640', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065801', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065962', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066123', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066284', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066445', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066606', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066767', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067089', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067250', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067411', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067572', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067733', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067894', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068216', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068377', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068538', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068699', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068860', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069021', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069182', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069343', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069504', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069665', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069826', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069987', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070148', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070309', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070470', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070631', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070792', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070953', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071114', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071275', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071436', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071597', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071758', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071919', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072080', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072241', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072402', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066928', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061776', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059200', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057912', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057268', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056946', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056785', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068055', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062742', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060005', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058556', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057751', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057429', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057107', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1674 | Q34 | What are the names of the genes that are targeted by the drug Febuxostat in the treatment of gout? | In the context of gout, the drug Febuxostat targets the gene xanthine dehydrogenase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gout%" OR LOWER(efo_term) LIKE "%gout%") AND (LOWER(drugName) LIKE "%febuxostat%" OR LOWER(tradeNames_list) LIKE "%febuxostat%" OR LOWER(syns_list) LIKE "%febuxostat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095560', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095524', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095515', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095542', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095551', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}, {'UUID': 'DrugTargetsIndication121923_text_1095533', 'drugName': 'Febuxostat', 'tradeNames_list': "['Adenuric', 'Uloric']", 'syns_list': "['Febuxostat', 'NSC-758874', 'TMX-67']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'XDH', 'approvedName': 'xanthine dehydrogenase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.86 | Q34 | What are the names of the genes that are targeted by the drug Pimavanserin Tartrate in the treatment of Hallucinations? | In the context of Hallucinations, the drug Pimavanserin Tartrate targets the gene 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hallucinations%" OR LOWER(efo_term) LIKE "%hallucinations%") AND (LOWER(drugName) LIKE "%pimavanserin tartrate%" OR LOWER(tradeNames_list) LIKE "%pimavanserin tartrate%" OR LOWER(syns_list) LIKE "%pimavanserin tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205116', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205131', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205136', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205141', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205151', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205156', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205161', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205171', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205176', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205181', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205186', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205196', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205201', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205206', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205211', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205216', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205221', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205226', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205231', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205236', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205241', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205246', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205166', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205126', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205106', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205096', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205091', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205191', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205146', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205121', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205111', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205101', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1663 | Q34 | What are the names of the genes that are targeted by the drug Spironolactone in the treatment of cirrhosis of liver? | In the context of cirrhosis of liver, the drug Spironolactone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cirrhosis of liver%" OR LOWER(efo_term) LIKE "%cirrhosis of liver%") AND (LOWER(drugName) LIKE "%spironolactone%" OR LOWER(tradeNames_list) LIKE "%spironolactone%" OR LOWER(syns_list) LIKE "%spironolactone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094543', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094657', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094619', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094467', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094353', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094391', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094581', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094505', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094429', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.331 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of pemphigus? | In the context of pemphigus, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pemphigus%" OR LOWER(efo_term) LIKE "%pemphigus%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226932', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227482', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227502', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227767', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228052', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228072', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228642', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228927', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229212', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229497', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229782', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230067', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230352', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230922', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231207', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231777', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232062', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232347', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230637', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227217', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226647', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226362', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231492', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227787', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227197', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226912', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226627', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.7 | Q34 | What are the names of the genes that are targeted by the drug Risperidone in the treatment of bipolar disorder? | In the context of bipolar disorder, the drug Risperidone targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar disorder%" OR LOWER(efo_term) LIKE "%bipolar disorder%") AND (LOWER(drugName) LIKE "%risperidone%" OR LOWER(tradeNames_list) LIKE "%risperidone%" OR LOWER(syns_list) LIKE "%risperidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149558', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149619', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149624', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149652', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149685', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149690', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149718', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149751', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149756', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149784', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149789', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149822', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149850', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149855', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149883', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149888', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149916', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149921', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149949', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149954', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149982', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150015', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150020', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150048', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150053', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150081', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150114', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150119', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150147', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150152', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150180', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150185', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150213', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150218', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150246', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150251', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150279', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150284', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150312', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150317', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150345', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150350', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150378', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150383', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150411', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150416', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150444', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150449', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150477', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150482', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150510', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150543', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150548', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150576', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150581', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150609', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150614', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150647', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150675', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150680', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150708', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150713', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150741', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150746', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150774', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150779', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150807', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150812', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150840', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150845', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150873', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150878', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150906', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150911', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150939', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150944', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150972', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150977', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151005', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151010', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151038', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151043', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151071', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151076', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151104', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151109', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150515', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149987', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149723', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149591', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149525', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149492', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149487', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150642', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150086', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149817', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149657', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149586', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149553', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149520', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1639 | Q34 | What are the names of the genes that are targeted by the drug Rimegepant Sulfate in the treatment of migraine disorder? | In the context of migraine disorder, the drug Rimegepant Sulfate targets the gene calcitonin receptor like receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%rimegepant sulfate%" OR LOWER(tradeNames_list) LIKE "%rimegepant sulfate%" OR LOWER(syns_list) LIKE "%rimegepant sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094056', 'drugName': 'Rimegepant Sulfate', 'tradeNames_list': "['Nurtec odt']", 'syns_list': "['Rimegepant sulfate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094053', 'drugName': 'Rimegepant Sulfate', 'tradeNames_list': "['Nurtec odt']", 'syns_list': "['Rimegepant sulfate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094054', 'drugName': 'Rimegepant Sulfate', 'tradeNames_list': "['Nurtec odt']", 'syns_list': "['Rimegepant sulfate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094057', 'drugName': 'Rimegepant Sulfate', 'tradeNames_list': "['Nurtec odt']", 'syns_list': "['Rimegepant sulfate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094055', 'drugName': 'Rimegepant Sulfate', 'tradeNames_list': "['Nurtec odt']", 'syns_list': "['Rimegepant sulfate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1706 | Q34 | What are the names of the genes that are targeted by the drug Degarelix Acetate in the treatment of prostate cancer? | In the context of prostate cancer, the drug Degarelix Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%degarelix acetate%" OR LOWER(tradeNames_list) LIKE "%degarelix acetate%" OR LOWER(syns_list) LIKE "%degarelix acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097137', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097141', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097125', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097149', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097161', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097133', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097157', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097153', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097129', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097145', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097126', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097142', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097146', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097150', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097122', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097130', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097138', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097154', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097158', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097134', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'syns_list': "['Degarelix (as acetate)', 'Degarelix acetate', 'Degarelix acetate hydrateFE-200486', 'FE200486', 'FE200486 (FREE BASE)']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1486 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of neoplasm? | In the context of neoplasm, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1058729', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057763', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057270', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058397', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056787', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057426', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057424', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057592', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057907', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058067', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058236', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058407', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056779', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059033', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058889', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056941', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056796', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059194', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059041', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059197', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057423', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057441', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057602', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057745', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057924', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057909', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058075', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058392', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057109', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058245', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057263', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058551', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057280', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058558', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058567', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059036', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058872', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058890', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056940', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059034', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056943', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056948', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056957', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059355', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056797', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059051', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059050', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059212', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059195', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059211', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059202', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057262', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057585', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057584', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057753', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057601', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057748', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058228', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057906', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057923', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057914', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058085', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058068', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058084', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057101', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058719', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057104', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058231', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057118', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058390', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057265', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058389', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058246', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058714', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058406', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058550', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057279', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058712', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058553', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058711', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058568', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059356', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057431', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058875', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058873', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059363', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059358', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058728', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058229', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057762', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057587', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057440', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056782', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057746', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058070', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057119', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058880', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056958', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057102', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056780', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.842 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of neoplasm? | In the context of neoplasm, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833160', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832945', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833382', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832937', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833492', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833167', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833500', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833056', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833049', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833271', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833389', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833048', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832938', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833159', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833278', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833270', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833381', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833493', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833014', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833376', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832928', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833022', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833125', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833358', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colonic neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833347', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833155', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833036', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833043', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833458', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833028', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833025', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colonic neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832933', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832932', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833457', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833462', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832930', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832914', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colonic neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833368', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colon carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833377', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833021', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833023', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832907', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833465', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833346', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833035', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colon carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833361', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833132', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833039', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833041', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833042', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833044', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833372', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833354', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833355', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833153', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833150', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832931', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832912', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833265', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833264', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833146', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colon carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833351', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833365', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833374', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833263', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833134', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832917', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833266', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833124', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833129', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833356', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833133', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833257', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colon carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833136', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colonic neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833258', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833139', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833143', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833147', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833369', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833152', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833247', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colonic neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832910', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832921', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833154', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833240', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833243', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833236', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832925', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833244', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833235', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833466', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833375', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833250', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833261', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833254', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832911', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832924', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colon carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833013', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833032', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832902', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.455 | Q34 | What are the names of the genes that are targeted by the drug Phenylephrine Hydrochloride in the treatment of Pruritus? | In the context of Pruritus, the drug Phenylephrine Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pruritus%" OR LOWER(efo_term) LIKE "%pruritus%") AND (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%phenylephrine hydrochloride%" OR LOWER(syns_list) LIKE "%phenylephrine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416697', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416625', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416607', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416661', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416679', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416643', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.494 | Q34 | What are the names of the genes that are targeted by the drug Phentermine Hydrochloride in the treatment of obesity? | In the context of obesity, the drug Phentermine Hydrochloride targets the gene solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%obesity%" OR LOWER(efo_term) LIKE "%obesity%") AND (LOWER(drugName) LIKE "%phentermine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%phentermine hydrochloride%" OR LOWER(syns_list) LIKE "%phentermine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434240', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_list': "['Adipex-p', 'Fastin', 'Lomaira', 'Obestin-30', 'Oby-trim', 'Ona-mastPhentermine hydrochloride', 'Suprenza', 'Tora', 'Wilpo']", 'syns_list': "['NSC-44090', 'Phentermine hcl', 'Phentermine hydrochloridePhentermine hydrochloride civ', 'Zantryl']", 'yearOfFirstApproval': 1973, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434241', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_list': "['Adipex-p', 'Fastin', 'Lomaira', 'Obestin-30', 'Oby-trim', 'Ona-mastPhentermine hydrochloride', 'Suprenza', 'Tora', 'Wilpo']", 'syns_list': "['NSC-44090', 'Phentermine hcl', 'Phentermine hydrochloridePhentermine hydrochloride civ', 'Zantryl']", 'yearOfFirstApproval': 1973, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434242', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_list': "['Adipex-p', 'Fastin', 'Lomaira', 'Obestin-30', 'Oby-trim', 'Ona-mastPhentermine hydrochloride', 'Suprenza', 'Tora', 'Wilpo']", 'syns_list': "['NSC-44090', 'Phentermine hcl', 'Phentermine hydrochloridePhentermine hydrochloride civ', 'Zantryl']", 'yearOfFirstApproval': 1973, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1467 | Q34 | What are the names of the genes that are targeted by the drug Trifarotene in the treatment of acne? | In the context of acne, the drug Trifarotene targets the gene retinoic acid receptor gamma. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%trifarotene%" OR LOWER(tradeNames_list) LIKE "%trifarotene%" OR LOWER(syns_list) LIKE "%trifarotene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055617', 'drugName': 'Trifarotene', 'tradeNames_list': "['Aklief']", 'syns_list': "['CD-5789', 'CD5789', 'Trifarotene']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055608', 'drugName': 'Trifarotene', 'tradeNames_list': "['Aklief']", 'syns_list': "['CD-5789', 'CD5789', 'Trifarotene']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055611', 'drugName': 'Trifarotene', 'tradeNames_list': "['Aklief']", 'syns_list': "['CD-5789', 'CD5789', 'Trifarotene']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055620', 'drugName': 'Trifarotene', 'tradeNames_list': "['Aklief']", 'syns_list': "['CD-5789', 'CD5789', 'Trifarotene']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055614', 'drugName': 'Trifarotene', 'tradeNames_list': "['Aklief']", 'syns_list': "['CD-5789', 'CD5789', 'Trifarotene']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.289 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of inflammation? | In the context of inflammation, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%inflammation%" OR LOWER(efo_term) LIKE "%inflammation%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226915', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227459', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227485', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227744', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228029', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228055', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228314', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228599', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228625', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228884', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228910', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229195', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229454', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229480', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229739', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229765', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230024', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230050', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230309', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230335', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230594', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230879', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230905', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231164', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231190', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231449', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231734', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231760', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232019', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232045', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232304', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232330', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230620', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228340', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227200', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226630', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226345', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226319', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231475', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229169', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227770', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227174', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226889', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226604', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1479 | Q34 | What are the names of the genes that are targeted by the drug Lusutrombopag in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Lusutrombopag targets the gene MPL proto-oncogene, thrombopoietin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%lusutrombopag%" OR LOWER(tradeNames_list) LIKE "%lusutrombopag%" OR LOWER(syns_list) LIKE "%lusutrombopag%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1056630', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056627', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056636', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056633', 'drugName': 'Lusutrombopag', 'tradeNames_list': "['Mulpleta', 'S-888711']", 'syns_list': "['Lusutrombopag', 'RSC888711', 'S-888711']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1968 | Q34 | What are the names of the genes that are targeted by the drug Sotorasib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Sotorasib targets the gene KRAS proto-oncogene, GTPase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%sotorasib%" OR LOWER(tradeNames_list) LIKE "%sotorasib%" OR LOWER(syns_list) LIKE "%sotorasib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193500', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193507', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1353 | Q34 | What are the names of the genes that are targeted by the drug Inclisiran Sodium in the treatment of atherosclerosis? | In the context of atherosclerosis, the drug Inclisiran Sodium targets the gene proprotein convertase subtilisin/kexin type 9. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atherosclerosis%" OR LOWER(efo_term) LIKE "%atherosclerosis%") AND (LOWER(drugName) LIKE "%inclisiran sodium%" OR LOWER(tradeNames_list) LIKE "%inclisiran sodium%" OR LOWER(syns_list) LIKE "%inclisiran sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993749', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993755', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993757', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993759', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993763', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993765', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993767', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993771', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993773', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993775', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993769', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993745', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993741', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993739', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993753', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993761', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993751', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993747', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993743', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1330 | Q34 | What are the names of the genes that are targeted by the drug Ceritinib in the treatment of cancer? | In the context of cancer, the drug Ceritinib targets the gene ALK receptor tyrosine kinase, EMAP like 4 and nucleophosmin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%ceritinib%" OR LOWER(tradeNames_list) LIKE "%ceritinib%" OR LOWER(syns_list) LIKE "%ceritinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_992314', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991729', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992106', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991833', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991599', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992431', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991651', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991703', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992002', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991755', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992132', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_992197', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991859', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992366', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991586', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992379', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991612', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992457', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991638', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992470', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991664', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991690', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991950', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991716', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992028', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991742', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991768', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992184', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991794', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992145', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991820', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992223', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991846', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992236', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991872', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992418', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991898', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992353', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991339', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992405', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991430', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992392', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991300', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992522', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991443', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992444', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991352', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992509', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991456', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992496', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_992483', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991469', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991924', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991365', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991976', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991482', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991963', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992080', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991495', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992015', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991378', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992067', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991508', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992054', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991287', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992288', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991521', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992119', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991391', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992171', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991534', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992158', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991326', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992275', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991547', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992210', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991404', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992262', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991560', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992249', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991274', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992535', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_991573', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992327', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991417', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992561', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_992548', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_992301', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_992093', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991989', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991937', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991911', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991677', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991313', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992041', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991807', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_992340', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991625', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991781', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991885', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.684 | Q34 | What are the names of the genes that are targeted by the drug Rivaroxaban in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Rivaroxaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%rivaroxaban%" OR LOWER(tradeNames_list) LIKE "%rivaroxaban%" OR LOWER(syns_list) LIKE "%rivaroxaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708854', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708959', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708994', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709029', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709099', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709134', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709169', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709239', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709274', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709309', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709344', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709414', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709449', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709484', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709519', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709554', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709589', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709624', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709659', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709694', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709729', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709799', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709834', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709869', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709904', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709939', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710009', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710044', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710079', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710114', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710149', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710184', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710219', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710254', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710289', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709764', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709204', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708924', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708784', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708714', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708679', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709974', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709379', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709064', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708889', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708819', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708749', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1958 | Q34 | What are the names of the genes that are targeted by the drug Vorapaxar Sulfate in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Vorapaxar Sulfate targets the gene coagulation factor II thrombin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%vorapaxar sulfate%" OR LOWER(tradeNames_list) LIKE "%vorapaxar sulfate%" OR LOWER(syns_list) LIKE "%vorapaxar sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193354', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': "['Zontivity']", 'syns_list': "['SCH 530348', 'SCH-530348', 'Vorapaxar sulfate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1193358', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': "['Zontivity']", 'syns_list': "['SCH 530348', 'SCH-530348', 'Vorapaxar sulfate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1687 | Q34 | What are the names of the genes that are targeted by the drug Empagliflozin in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Empagliflozin targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%empagliflozin%" OR LOWER(tradeNames_list) LIKE "%empagliflozin%" OR LOWER(syns_list) LIKE "%empagliflozin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096521', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096602', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096629', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096656', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096710', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096737', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096764', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096791', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096575', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096467', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096413', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096386', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096683', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096548', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096494', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096440', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.772 | Q34 | What are the names of the genes that are targeted by the drug Naloxone Hydrochloride in the treatment of pain? | In the context of pain, the drug Naloxone Hydrochloride targets the gene opioid receptor mu 1, opioid receptor kappa 1 and opioid receptor delta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%naloxone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%naloxone hydrochloride%" OR LOWER(syns_list) LIKE "%naloxone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_789394', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789415', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789422', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789429', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789443', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789450', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789457', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789471', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789478', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789485', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789492', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789506', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789513', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789520', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789527', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789534', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789541', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789548', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789555', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789562', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789569', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789583', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789590', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789597', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789604', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789611', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789625', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789632', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789639', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789646', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789653', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789660', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789667', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789674', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789681', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789688', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789695', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789702', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789709', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789716', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789723', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789730', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789737', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789744', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789751', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789758', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789765', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789772', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789779', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789786', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789793', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789807', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789814', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789821', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789828', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789835', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789842', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789856', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789863', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789870', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789877', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789884', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789891', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789898', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789905', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789912', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789919', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789926', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789933', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789940', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789947', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789954', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789961', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789968', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789975', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789982', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789989', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789996', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790003', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790010', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790017', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790024', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790031', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790038', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790045', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790052', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_789800', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789576', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789464', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789408', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789380', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789366', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789359', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789849', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789618', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789499', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789436', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789401', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789387', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789373', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.847 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of ankylosing spondylitis? | In the context of ankylosing spondylitis, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ankylosing spondylitis%" OR LOWER(efo_term) LIKE "%ankylosing spondylitis%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833499', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833055', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832944', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833277', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833388', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833166', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1174 | Q34 | What are the names of the genes that are targeted by the drug Linagliptin in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Linagliptin targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%linagliptin%" OR LOWER(tradeNames_list) LIKE "%linagliptin%" OR LOWER(syns_list) LIKE "%linagliptin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_932927', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932946', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932947', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932956', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932966', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932967', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932976', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932986', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932987', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932996', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932997', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933007', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933016', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933017', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933026', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933027', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933036', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933037', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932977', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932937', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932917', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932907', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932906', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933006', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932957', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932936', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932926', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_932916', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'syns_list': "['BI 1356', 'BI 1356 BS', 'BI-1356', 'BI-1356-BS', 'BI-1356BS', 'BS 1356 BSBS-1356-BS', 'Linagliptin', 'Trazenta']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1082 | Q34 | What are the names of the genes that are targeted by the drug Enzalutamide in the treatment of prostate carcinoma? | In the context of prostate carcinoma, the drug Enzalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate carcinoma%" OR LOWER(efo_term) LIKE "%prostate carcinoma%") AND (LOWER(drugName) LIKE "%enzalutamide%" OR LOWER(tradeNames_list) LIKE "%enzalutamide%" OR LOWER(syns_list) LIKE "%enzalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921127', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921184', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921203', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921222', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921260', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921279', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921298', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921336', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921355', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921317', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921165', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921051', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921032', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921089', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921241', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921146', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921108', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921070', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1636 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of hematoma? | Dabigatran has not been approved by the FDA as a treatment for hematoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hematoma%" OR LOWER(efo_term) LIKE "%hematoma%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093469', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093502', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093513', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093524', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093546', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093557', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093568', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093590', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093601', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093612', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093623', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093645', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093656', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093667', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093678', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093689', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093700', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093711', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093722', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093733', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093744', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093766', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093777', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093788', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093799', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093810', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093832', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093843', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093854', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093865', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093876', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093887', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093898', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093909', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093920', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093931', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093942', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093953', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093964', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093975', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093986', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093997', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094008', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094019', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094030', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093755', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093579', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093491', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093447', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093425', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093414', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093821', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093634', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093535', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093480', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093458', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093436', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.329 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of dermatitis herpetiformis? | In the context of dermatitis herpetiformis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dermatitis herpetiformis%" OR LOWER(efo_term) LIKE "%dermatitis herpetiformis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227785', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228640', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228925', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229210', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229780', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230065', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230350', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230920', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231205', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231490', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231775', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232345', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230635', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228355', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227215', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226645', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226360', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232060', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229495', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228070', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227500', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226930', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis Herpetiformis', 'efo_term': 'dermatitis herpetiformis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1013 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857479', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.750 | Q34 | What are the names of the genes that are targeted by the drug Tramadol Hydrochloride in the treatment of Chronic pain? | In the context of Chronic pain, the drug Tramadol Hydrochloride targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic pain%" OR LOWER(efo_term) LIKE "%chronic pain%") AND (LOWER(drugName) LIKE "%tramadol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%tramadol hydrochloride%" OR LOWER(syns_list) LIKE "%tramadol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_766777', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_list': "['Aceon', 'Conzip', 'Dromadol sr', 'Dromadol xl', 'Invodol sr', 'Larapam srMabron', 'Maneo', 'Marol', 'Maxitram sr', 'Nobligan ret', 'Oldaram', 'QdoloRybix odt', 'Ryzolt', 'Tilodol sr', 'Tradorec xl', 'TramacetTramadol hydrochloride', 'Tramake', 'Tramake insts', 'Tramquel srTramulief sr', 'Ultram', 'Ultram er', 'Zamadol', 'Zamadol 24hrZamadol melt', 'Zamadol sr', 'Zeridame sr', 'Zydol', 'Zydol sr', 'Zydol xl']", 'syns_list': "['Amadol', 'CG-315', 'CG-315E', 'Contramal', 'NIH-10969', 'NSC-759105Tradonal', 'Tramadol hcl', 'Tramadol hydrochlorideTramadol hydrochloride civ', 'Tramal', 'U-26,225A', 'U-26225A', 'ZamudolZertane']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766763', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_list': "['Aceon', 'Conzip', 'Dromadol sr', 'Dromadol xl', 'Invodol sr', 'Larapam srMabron', 'Maneo', 'Marol', 'Maxitram sr', 'Nobligan ret', 'Oldaram', 'QdoloRybix odt', 'Ryzolt', 'Tilodol sr', 'Tradorec xl', 'TramacetTramadol hydrochloride', 'Tramake', 'Tramake insts', 'Tramquel srTramulief sr', 'Ultram', 'Ultram er', 'Zamadol', 'Zamadol 24hrZamadol melt', 'Zamadol sr', 'Zeridame sr', 'Zydol', 'Zydol sr', 'Zydol xl']", 'syns_list': "['Amadol', 'CG-315', 'CG-315E', 'Contramal', 'NIH-10969', 'NSC-759105Tradonal', 'Tramadol hcl', 'Tramadol hydrochlorideTramadol hydrochloride civ', 'Tramal', 'U-26,225A', 'U-26225A', 'ZamudolZertane']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766749', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_list': "['Aceon', 'Conzip', 'Dromadol sr', 'Dromadol xl', 'Invodol sr', 'Larapam srMabron', 'Maneo', 'Marol', 'Maxitram sr', 'Nobligan ret', 'Oldaram', 'QdoloRybix odt', 'Ryzolt', 'Tilodol sr', 'Tradorec xl', 'TramacetTramadol hydrochloride', 'Tramake', 'Tramake insts', 'Tramquel srTramulief sr', 'Ultram', 'Ultram er', 'Zamadol', 'Zamadol 24hrZamadol melt', 'Zamadol sr', 'Zeridame sr', 'Zydol', 'Zydol sr', 'Zydol xl']", 'syns_list': "['Amadol', 'CG-315', 'CG-315E', 'Contramal', 'NIH-10969', 'NSC-759105Tradonal', 'Tramadol hcl', 'Tramadol hydrochlorideTramadol hydrochloride civ', 'Tramal', 'U-26,225A', 'U-26225A', 'ZamudolZertane']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766742', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_list': "['Aceon', 'Conzip', 'Dromadol sr', 'Dromadol xl', 'Invodol sr', 'Larapam srMabron', 'Maneo', 'Marol', 'Maxitram sr', 'Nobligan ret', 'Oldaram', 'QdoloRybix odt', 'Ryzolt', 'Tilodol sr', 'Tradorec xl', 'TramacetTramadol hydrochloride', 'Tramake', 'Tramake insts', 'Tramquel srTramulief sr', 'Ultram', 'Ultram er', 'Zamadol', 'Zamadol 24hrZamadol melt', 'Zamadol sr', 'Zeridame sr', 'Zydol', 'Zydol sr', 'Zydol xl']", 'syns_list': "['Amadol', 'CG-315', 'CG-315E', 'Contramal', 'NIH-10969', 'NSC-759105Tradonal', 'Tramadol hcl', 'Tramadol hydrochlorideTramadol hydrochloride civ', 'Tramal', 'U-26,225A', 'U-26225A', 'ZamudolZertane']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766784', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_list': "['Aceon', 'Conzip', 'Dromadol sr', 'Dromadol xl', 'Invodol sr', 'Larapam srMabron', 'Maneo', 'Marol', 'Maxitram sr', 'Nobligan ret', 'Oldaram', 'QdoloRybix odt', 'Ryzolt', 'Tilodol sr', 'Tradorec xl', 'TramacetTramadol hydrochloride', 'Tramake', 'Tramake insts', 'Tramquel srTramulief sr', 'Ultram', 'Ultram er', 'Zamadol', 'Zamadol 24hrZamadol melt', 'Zamadol sr', 'Zeridame sr', 'Zydol', 'Zydol sr', 'Zydol xl']", 'syns_list': "['Amadol', 'CG-315', 'CG-315E', 'Contramal', 'NIH-10969', 'NSC-759105Tradonal', 'Tramadol hcl', 'Tramadol hydrochlorideTramadol hydrochloride civ', 'Tramal', 'U-26,225A', 'U-26225A', 'ZamudolZertane']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766770', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_list': "['Aceon', 'Conzip', 'Dromadol sr', 'Dromadol xl', 'Invodol sr', 'Larapam srMabron', 'Maneo', 'Marol', 'Maxitram sr', 'Nobligan ret', 'Oldaram', 'QdoloRybix odt', 'Ryzolt', 'Tilodol sr', 'Tradorec xl', 'TramacetTramadol hydrochloride', 'Tramake', 'Tramake insts', 'Tramquel srTramulief sr', 'Ultram', 'Ultram er', 'Zamadol', 'Zamadol 24hrZamadol melt', 'Zamadol sr', 'Zeridame sr', 'Zydol', 'Zydol sr', 'Zydol xl']", 'syns_list': "['Amadol', 'CG-315', 'CG-315E', 'Contramal', 'NIH-10969', 'NSC-759105Tradonal', 'Tramadol hcl', 'Tramadol hydrochlorideTramadol hydrochloride civ', 'Tramal', 'U-26,225A', 'U-26225A', 'ZamudolZertane']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766756', 'drugName': 'Tramadol Hydrochloride', 'tradeNames_list': "['Aceon', 'Conzip', 'Dromadol sr', 'Dromadol xl', 'Invodol sr', 'Larapam srMabron', 'Maneo', 'Marol', 'Maxitram sr', 'Nobligan ret', 'Oldaram', 'QdoloRybix odt', 'Ryzolt', 'Tilodol sr', 'Tradorec xl', 'TramacetTramadol hydrochloride', 'Tramake', 'Tramake insts', 'Tramquel srTramulief sr', 'Ultram', 'Ultram er', 'Zamadol', 'Zamadol 24hrZamadol melt', 'Zamadol sr', 'Zeridame sr', 'Zydol', 'Zydol sr', 'Zydol xl']", 'syns_list': "['Amadol', 'CG-315', 'CG-315E', 'Contramal', 'NIH-10969', 'NSC-759105Tradonal', 'Tramadol hcl', 'Tramadol hydrochlorideTramadol hydrochloride civ', 'Tramal', 'U-26,225A', 'U-26225A', 'ZamudolZertane']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1068 | Q34 | What are the names of the genes that are targeted by the drug Ticagrelor in the treatment of coronary artery disease? | In the context of coronary artery disease, the drug Ticagrelor targets the gene purinergic receptor P2Y12. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary artery disease%" OR LOWER(efo_term) LIKE "%coronary artery disease%") AND (LOWER(drugName) LIKE "%ticagrelor%" OR LOWER(tradeNames_list) LIKE "%ticagrelor%" OR LOWER(syns_list) LIKE "%ticagrelor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_920467', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920545', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920571', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920597', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920649', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920675', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920701', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920753', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920779', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920805', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920831', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920883', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920909', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920935', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920961', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920987', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920727', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920519', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920415', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920363', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920337', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920857', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920623', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920493', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920441', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920389', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.892 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of Dysmenorrhea? | In the context of Dysmenorrhea, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dysmenorrhea%" OR LOWER(efo_term) LIKE "%dysmenorrhea%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838128', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838179', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838196', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838213', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838247', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838264', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838281', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838298', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838162', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838094', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838060', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838043', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838230', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838145', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838111', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838077', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1918 | Q34 | What are the names of the genes that are targeted by the drug Mipomersen Sodium in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Mipomersen Sodium targets the gene apolipoprotein B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%mipomersen sodium%" OR LOWER(tradeNames_list) LIKE "%mipomersen sodium%" OR LOWER(syns_list) LIKE "%mipomersen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191788', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'syns_list': "['ISIS 301012', 'ISIS-301012', 'Mipomersen sodium', 'Mipomersen sodium salt']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B'}, {'UUID': 'DrugTargetsIndication121923_text_1191791', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'syns_list': "['ISIS 301012', 'ISIS-301012', 'Mipomersen sodium', 'Mipomersen sodium salt']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B'}, {'UUID': 'DrugTargetsIndication121923_text_1191794', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'syns_list': "['ISIS 301012', 'ISIS-301012', 'Mipomersen sodium', 'Mipomersen sodium salt']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.179 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of Stevens-Johnson syndrome? | In the context of Stevens-Johnson syndrome, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stevens-johnson syndrome%" OR LOWER(efo_term) LIKE "%stevens-johnson syndrome%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218685', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219309', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219517', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219725', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220141', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220349', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220557', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220765', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219101', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218269', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217853', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217645', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219933', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218893', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218477', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218061', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1434 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of angina pectoris? | In the context of angina pectoris, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%angina pectoris%" OR LOWER(efo_term) LIKE "%angina pectoris%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043685', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043699', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043710', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043711', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043724', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043725', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043727', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043739', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043741', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043752', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043753', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043766', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043767', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043769', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043780', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043781', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043783', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043794', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043795', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043797', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043808', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043811', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043822', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043823', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043825', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043836', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043839', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043850', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043851', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043853', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043864', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043865', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043867', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043878', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043879', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043881', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043892', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043893', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043895', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043906', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043907', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043909', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043920', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043921', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043923', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043934', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043935', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043937', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043948', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043949', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043951', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043963', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043965', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043976', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043977', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043979', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043990', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043993', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043962', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043809', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043738', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043697', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043682', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043669', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043668', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043991', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043837', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043755', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043713', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043696', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043683', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043671', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1172 | Q34 | What are the names of the genes that are targeted by the drug Selumetinib Sulfate in the treatment of neurofibromatosis? | In the context of neurofibromatosis, the drug Selumetinib Sulfate targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neurofibromatosis%" OR LOWER(efo_term) LIKE "%neurofibromatosis%") AND (LOWER(drugName) LIKE "%selumetinib sulfate%" OR LOWER(tradeNames_list) LIKE "%selumetinib sulfate%" OR LOWER(syns_list) LIKE "%selumetinib sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_932819', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932830', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932831', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932836', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932842', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932843', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932848', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932854', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932855', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932860', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932861', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932867', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932872', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932873', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932878', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932879', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932884', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932885', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932890', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932891', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932896', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932897', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932849', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932825', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932813', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932807', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932806', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932866', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932837', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932824', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932818', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932812', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.88 | Q34 | What are the names of the genes that are targeted by the drug Pimavanserin Tartrate in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Pimavanserin Tartrate targets the gene 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%pimavanserin tartrate%" OR LOWER(tradeNames_list) LIKE "%pimavanserin tartrate%" OR LOWER(syns_list) LIKE "%pimavanserin tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205118', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205133', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205138', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205143', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205153', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205158', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205163', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205173', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205178', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205183', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205188', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205198', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205203', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205208', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205213', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205218', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205223', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205228', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205233', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205238', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205243', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205248', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205168', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205128', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205108', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205098', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205093', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205193', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205148', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205123', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205113', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205103', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1749 | Q34 | What are the names of the genes that are targeted by the drug Esomeprazole Magnesium in the treatment of gastric ulcer? | In the context of gastric ulcer, the drug Esomeprazole Magnesium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastric ulcer%" OR LOWER(efo_term) LIKE "%gastric ulcer%") AND (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_list) LIKE "%esomeprazole magnesium%" OR LOWER(syns_list) LIKE "%esomeprazole magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097876', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097864', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097900', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097888', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1881 | Q34 | What are the names of the genes that are targeted by the drug Cobicistat in the treatment of HIV infection? | In the context of HIV infection, the drug Cobicistat targets the gene cytochrome P450 family 3 subfamily A member 4, cytochrome P450 family 3 subfamily A member 5, cytochrome P450 family 3 subfamily A member 43 and cytochrome P450 family 3 subfamily A member 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hiv infection%" OR LOWER(efo_term) LIKE "%hiv infection%") AND (LOWER(drugName) LIKE "%cobicistat%" OR LOWER(tradeNames_list) LIKE "%cobicistat%" OR LOWER(syns_list) LIKE "%cobicistat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148800', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148820', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148822', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148831', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148842', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148844', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148853', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148864', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148866', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148875', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148877', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148888', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148897', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148899', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148908', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148910', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148919', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148921', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148930', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148932', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148941', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148943', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148855', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148811', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148789', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148778', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148776', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148886', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148833', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148809', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148798', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148787', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.461 | Q34 | What are the names of the genes that are targeted by the drug Phenylephrine Hydrochloride in the treatment of sinusitis? | In the context of sinusitis, the drug Phenylephrine Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sinusitis%" OR LOWER(efo_term) LIKE "%sinusitis%") AND (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%phenylephrine hydrochloride%" OR LOWER(syns_list) LIKE "%phenylephrine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416703', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416631', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416613', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416667', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416685', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416649', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1812 | Q34 | What are the names of the genes that are targeted by the drug Montelukast Sodium in the treatment of Rhinitis, Allergic, Perennial? | In the context of Rhinitis, Allergic, Perennial, the drug Montelukast Sodium targets the gene cysteinyl leukotriene receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rhinitis, allergic, perennial%" OR LOWER(efo_term) LIKE "%rhinitis, allergic, perennial%") AND (LOWER(drugName) LIKE "%montelukast sodium%" OR LOWER(tradeNames_list) LIKE "%montelukast sodium%" OR LOWER(syns_list) LIKE "%montelukast sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100395', 'drugName': 'Montelukast Sodium', 'tradeNames_list': "['Montelukast sodium', 'Singulair']", 'syns_list': "['MK-476', 'Montelukast (as sodium)', 'Montelukast monosodium saltMontelukast sodium', 'NSC-759107']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.55 | Q34 | What are the names of the genes that are targeted by the drug Asenapine in the treatment of schizophrenia? | In the context of schizophrenia, the drug Asenapine targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%asenapine%" OR LOWER(tradeNames_list) LIKE "%asenapine%" OR LOWER(syns_list) LIKE "%asenapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197591', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197609', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197615', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197621', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197633', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197639', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197645', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197657', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197663', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197669', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197675', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197687', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197693', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197699', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197705', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197711', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197717', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197723', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197729', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197735', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197741', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197753', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197759', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197765', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197771', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197777', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197789', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197795', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197801', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197807', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197810', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197813', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197816', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197819', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197822', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197825', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197828', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197831', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197834', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197837', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197840', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197843', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197846', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197849', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197852', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197855', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197858', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197861', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197864', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197867', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197870', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197876', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197879', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197882', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197885', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197888', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197891', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197897', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197873', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197747', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197651', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197603', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197579', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197567', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197561', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197894', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197783', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197681', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197627', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197597', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197585', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197573', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1488 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057589', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058072', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058233', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058394', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058716', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058877', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059038', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059360', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059521', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059682', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059843', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060165', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060326', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060487', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060648', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060809', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060970', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061131', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061292', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061453', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061614', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061936', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062097', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062258', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062419', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062580', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062902', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063063', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063224', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063385', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063546', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063707', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063868', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064029', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064190', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064351', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064512', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064673', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064834', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064995', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065156', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065317', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065478', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065639', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065800', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065961', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066122', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066283', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066444', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066605', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066766', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067088', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067249', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067410', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067571', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067732', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067893', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068215', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068376', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068537', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068698', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068859', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069020', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069181', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069342', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069503', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069664', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069825', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069986', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070147', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070308', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070469', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070630', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070791', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070952', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071113', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071274', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071435', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071596', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071757', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071918', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072079', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072240', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072401', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066927', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061775', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059199', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057911', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057267', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056945', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056784', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068054', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062741', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060004', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058555', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057750', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057428', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057106', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.648 | Q34 | What are the names of the genes that are targeted by the drug Lenvatinib in the treatment of thyroid cancer? | In the context of thyroid cancer, the drug Lenvatinib targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid cancer%" OR LOWER(efo_term) LIKE "%thyroid cancer%") AND (LOWER(drugName) LIKE "%lenvatinib%" OR LOWER(tradeNames_list) LIKE "%lenvatinib%" OR LOWER(syns_list) LIKE "%lenvatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_690184', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690214', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690224', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690234', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690254', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690264', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690274', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690294', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690304', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690314', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690324', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690344', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690354', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690364', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690374', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690384', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690394', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690404', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690414', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690424', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690434', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690454', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690464', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690474', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690484', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690540', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690652', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690708', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690764', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690820', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690876', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690932', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690988', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_691044', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_691100', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_691156', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_691212', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691268', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691324', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691380', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691436', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691492', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691548', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691604', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691660', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691716', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691772', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691828', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_691884', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_691940', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_691996', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692108', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692164', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692220', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692276', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692332', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692388', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692500', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_692052', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690444', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690284', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690204', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690164', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690144', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690134', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_692444', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690596', 'drugName': 'Lenvatinib', 'tradeNames_list': "['Kisplyx', 'Lenvima']", 'syns_list': "['E-7080', 'ER-203492-00', 'Lenvatinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690334', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690244', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690194', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690174', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690154', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.682 | Q34 | What are the names of the genes that are targeted by the drug Erdafitinib in the treatment of urinary bladder cancer? | In the context of urinary bladder cancer, the drug Erdafitinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2 and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urinary bladder cancer%" OR LOWER(efo_term) LIKE "%urinary bladder cancer%") AND (LOWER(drugName) LIKE "%erdafitinib%" OR LOWER(tradeNames_list) LIKE "%erdafitinib%" OR LOWER(syns_list) LIKE "%erdafitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707177', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707225', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707241', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707257', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707289', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707305', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707321', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707353', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707369', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707385', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707401', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707433', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707449', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707465', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707481', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707497', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707513', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707529', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707545', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707561', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707577', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707609', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707625', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707641', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707657', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707673', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707705', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707721', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707737', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707753', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707769', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707785', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707801', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707817', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707833', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707849', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707865', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707881', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707897', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707913', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707929', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707945', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707961', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707977', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707993', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708009', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708025', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708041', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708057', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708073', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708089', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708121', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708137', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708153', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708169', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708185', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708201', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708233', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708249', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708265', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708281', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708297', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708313', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708329', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708345', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708361', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708377', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708393', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708409', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708425', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708441', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708457', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708473', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708489', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708505', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708521', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708537', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708553', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708569', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708585', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708601', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708617', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708105', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707593', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707337', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707209', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707145', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707113', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707097', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708217', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707689', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707417', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707273', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707193', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707161', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707129', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.223 | Q34 | What are the names of the genes that are targeted by the drug Betamethasone Dipropionate in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Betamethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%betamethasone dipropionate%" OR LOWER(syns_list) LIKE "%betamethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220890', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220866', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220842', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220830', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220902', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220878', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220854', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.115 | Q34 | What are the names of the genes that are targeted by the drug Duloxetine Hydrochloride in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Duloxetine Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%duloxetine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%duloxetine hydrochloride%" OR LOWER(syns_list) LIKE "%duloxetine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206080', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206128', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206144', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206160', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206192', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206208', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206224', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206256', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206272', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206288', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206304', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206336', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206352', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206368', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206384', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206400', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206416', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206432', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206448', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206464', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206480', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206496', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206240', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206112', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206048', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206016', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206000', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206320', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206176', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206096', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206064', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206032', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.947 | Q34 | What are the names of the genes that are targeted by the drug Ketorolac Tromethamine in the treatment of pain? | In the context of pain, the drug Ketorolac Tromethamine targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%ketorolac tromethamine%" OR LOWER(tradeNames_list) LIKE "%ketorolac tromethamine%" OR LOWER(syns_list) LIKE "%ketorolac tromethamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842137', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841769', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841814', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841800', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841782', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841977', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841816', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842009', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842041', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841832', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842200', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842105', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841848', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842248', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841801', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841961', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841864', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842264', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842152', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841768', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841880', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841817', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842025', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841896', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842182', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841830', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841912', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842214', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841833', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842089', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841928', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842216', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841846', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842121', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841944', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842262', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841849', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841958', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841960', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842249', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841862', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841785', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842073', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841993', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841865', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841990', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841992', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842265', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841878', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842006', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842008', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841881', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842022', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842024', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842168', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841894', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842038', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842185', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841897', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842054', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842056', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842184', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841910', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842070', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842072', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842232', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841913', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842086', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842088', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842201', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841926', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842102', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842104', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842230', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841929', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842118', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842120', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842217', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841942', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842134', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842136', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842150', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841945', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842233', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842198', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842169', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842166', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842153', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841976', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841974', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842040', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842057', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841798', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842246', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841784', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841766', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841972', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841876', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841988', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842004', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1215 | Q34 | What are the names of the genes that are targeted by the drug Propranolol Hydrochloride in the treatment of coronary atherosclerosis? | In the context of coronary atherosclerosis, the drug Propranolol Hydrochloride targets the gene adrenoceptor beta 2 and adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary atherosclerosis%" OR LOWER(efo_term) LIKE "%coronary atherosclerosis%") AND (LOWER(drugName) LIKE "%propranolol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%propranolol hydrochloride%" OR LOWER(syns_list) LIKE "%propranolol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937046', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937023', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937092', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937069', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1459 | Q34 | What are the names of the genes that are targeted by the drug Tretinoin in the treatment of freckles? | In the context of freckles, the drug Tretinoin targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%freckles%" OR LOWER(efo_term) LIKE "%freckles%") AND (LOWER(drugName) LIKE "%tretinoin%" OR LOWER(tradeNames_list) LIKE "%tretinoin%" OR LOWER(syns_list) LIKE "%tretinoin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1053725', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1053561', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053520', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053643', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053684', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1053602', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.176 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218682', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219306', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219514', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219722', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220138', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220346', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220554', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220762', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219098', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218266', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217850', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217642', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219930', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218890', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218474', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218058', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.757 | Q34 | What are the names of the genes that are targeted by the drug Oxycodone in the treatment of pain? | In the context of pain, the drug Oxycodone targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%oxycodone%" OR LOWER(tradeNames_list) LIKE "%oxycodone%" OR LOWER(syns_list) LIKE "%oxycodone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_766861', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766806', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766905', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766855', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766798', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766833', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766804', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766841', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766819', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766820', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766944', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766917', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766800', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766958', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766811', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766812', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766832', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766960', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766834', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766877', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766814', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766805', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766889', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766818', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766895', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766846', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766848', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766946', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766821', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766911', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766807', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766947', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766825', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766826', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766860', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766959', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766862', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766863', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766828', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766867', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766868', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766869', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766870', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766965', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766874', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766875', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766876', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766961', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766835', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766881', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766882', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766884', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766840', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766888', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766933', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766890', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766891', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766939', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766896', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766897', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766898', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766938', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766902', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766903', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766904', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766952', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766849', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766909', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766910', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766945', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766912', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766854', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766916', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766951', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766918', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766919', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766856', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766923', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766924', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766925', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766926', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766966', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766930', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766931', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766932', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766968', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766967', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766953', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766940', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766937', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766883', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766839', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766799', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766842', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766847', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766853', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766954', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766813', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766797', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766827', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.594 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of Seizure? | In the context of Seizure, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seizure%" OR LOWER(efo_term) LIKE "%seizure%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653030', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653061', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653086', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653087', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653117', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653118', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653123', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653149', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653154', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653179', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653180', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653210', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653211', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653216', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653241', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653242', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653247', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653272', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653273', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653278', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653303', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653309', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653334', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653335', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653340', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653365', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653371', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653396', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653397', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653402', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653427', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653428', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653433', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653458', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653459', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653464', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653489', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653490', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653495', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653520', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653521', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653526', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653551', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653552', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653557', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653582', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653583', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653588', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653613', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653614', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653619', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653645', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653650', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653675', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653676', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653681', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653706', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653712', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653737', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653738', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653743', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653768', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653769', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653774', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653799', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653800', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653805', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653830', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653831', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653836', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653861', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653862', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653867', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653892', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653893', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653898', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653923', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653924', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653929', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653954', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653955', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653960', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653985', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653986', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653991', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654016', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653644', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653304', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653148', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653056', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653024', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652994', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652993', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653707', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653366', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653185', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653092', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653055', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653025', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652999', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1545 | Q34 | What are the names of the genes that are targeted by the drug Cannabidiol in the treatment of Dravet syndrome? | In the context of Dravet syndrome, the drug Cannabidiol targets the gene cannabinoid receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dravet syndrome%" OR LOWER(efo_term) LIKE "%dravet syndrome%") AND (LOWER(drugName) LIKE "%cannabidiol%" OR LOWER(tradeNames_list) LIKE "%cannabidiol%" OR LOWER(syns_list) LIKE "%cannabidiol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073765', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073984', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074057', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074130', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074276', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074349', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074422', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074568', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074641', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074714', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074787', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074933', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075006', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075079', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075152', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075225', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075298', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075371', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075444', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075517', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075590', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075736', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075809', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075882', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075955', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076028', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076174', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076247', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076320', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075663', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074495', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073911', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073619', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073473', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073400', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076101', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074860', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074203', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073838', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073692', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073546', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.19 | Q34 | What are the names of the genes that are targeted by the drug Trazodone Hydrochloride in the treatment of unipolar depression? | In the context of unipolar depression, the drug Trazodone Hydrochloride targets the gene 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A and solute carrier family 6 member 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%trazodone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%trazodone hydrochloride%" OR LOWER(syns_list) LIKE "%trazodone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155401', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155410', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155411', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155415', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155420', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155421', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155425', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155430', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155431', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155435', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155436', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155441', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155445', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155446', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155450', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155451', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155455', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155456', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155460', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155461', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155465', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155470', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155471', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155475', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155476', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155480', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155485', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155486', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155490', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155491', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155495', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155496', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155500', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155501', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155505', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155506', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155466', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155426', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155406', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155396', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155391', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155390', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155481', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_155440', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_155416', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155405', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155400', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155395', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'syns_list': "['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.426 | Q34 | What are the names of the genes that are targeted by the drug Treprostinil in the treatment of pulmonary hypertension? | In the context of pulmonary hypertension, the drug Treprostinil targets the gene prostaglandin I2 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary hypertension%" OR LOWER(efo_term) LIKE "%pulmonary hypertension%") AND (LOWER(drugName) LIKE "%treprostinil%" OR LOWER(tradeNames_list) LIKE "%treprostinil%" OR LOWER(syns_list) LIKE "%treprostinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_245012', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245964', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245913', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245182', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244876', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244859', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244893', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245046', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245403', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245080', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245573', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245658', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245216', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245879', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245709', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245896', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245862', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245250', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244655', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245828', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244961', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244995', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245335', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245029', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245437', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245063', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245097', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245641', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245131', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245590', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245165', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245692', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245199', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244519', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245233', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244825', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245267', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245386', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244536', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244944', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245114', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244638', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245811', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244927', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244672', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245981', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244553', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244451', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244689', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245947', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244842', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244706', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245301', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244570', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245369', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244723', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245352', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245505', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244740', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245420', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244587', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245488', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244757', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245471', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244468', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245777', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244774', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245556', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244604', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245624', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244791', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245607', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245539', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245760', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244808', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245675', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244621', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245743', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245794', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245522', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245726', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245318', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245284', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244978', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245930', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244485', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244502', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245454', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245148', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245845', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244910', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244906', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244498', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244685', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244923', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244940', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244566', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244957', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244702', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244974', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'primary pulmonary hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1328 | Q34 | What are the names of the genes that are targeted by the drug Lorlatinib in the treatment of neoplasm? | In the context of neoplasm, the drug Lorlatinib targets the gene ALK receptor tyrosine kinase and EMAP like 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%lorlatinib%" OR LOWER(tradeNames_list) LIKE "%lorlatinib%" OR LOWER(syns_list) LIKE "%lorlatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_991046', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991060', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991062', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991068', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991076', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991078', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991084', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991092', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991094', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991100', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991102', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991110', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991116', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991118', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991124', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991126', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991132', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991134', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991140', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991142', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991148', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991156', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991158', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991164', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991166', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991172', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991180', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991182', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991188', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991190', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991196', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991198', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991204', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991206', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991212', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991214', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991220', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991222', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991228', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991230', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991236', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991238', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991244', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991246', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991252', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991254', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991260', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991262', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991150', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991086', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991054', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991038', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991030', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991028', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991174', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991108', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991070', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991052', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991044', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991036', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.287 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Peptic ulcer? | In the context of Peptic ulcer, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peptic ulcer%" OR LOWER(efo_term) LIKE "%peptic ulcer%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227742', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228597', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228882', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229167', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229737', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230022', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230307', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230877', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231162', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231447', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231732', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232302', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230592', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228312', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227172', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226602', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226317', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232017', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229452', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228027', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227457', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226887', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1569 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of Adenoma sebaceum? | In the context of Adenoma sebaceum, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%adenoma sebaceum%" OR LOWER(efo_term) LIKE "%adenoma sebaceum%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085627', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086032', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086167', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086302', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086572', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086707', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086842', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087112', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087247', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087382', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087517', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087787', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087922', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088057', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088192', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088327', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088462', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088597', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088732', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088867', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089002', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089272', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089407', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089542', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089677', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089812', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090082', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090217', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090352', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090487', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090622', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089137', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086977', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085897', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085357', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085087', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084952', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089947', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087652', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086437', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085762', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085492', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085222', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.432 | Q34 | What are the names of the genes that are targeted by the drug Carvedilol in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Carvedilol targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%carvedilol%" OR LOWER(tradeNames_list) LIKE "%carvedilol%" OR LOWER(syns_list) LIKE "%carvedilol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_357135', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357231', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357263', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357295', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357359', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357391', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357423', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357487', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357519', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357551', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357583', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357647', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357679', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357711', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357743', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357775', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357807', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357839', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357871', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357903', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357935', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357999', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358031', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358063', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358095', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358127', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358191', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358223', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358255', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358287', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358319', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358351', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358383', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358415', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358447', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358479', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358511', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358543', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358575', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358607', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358639', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358671', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358703', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358735', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358767', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358799', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358831', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358863', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358895', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358927', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358959', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359023', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359055', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359087', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359119', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359151', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359183', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359247', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359279', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359311', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359343', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359375', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359407', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359439', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359471', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359503', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359535', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359567', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359599', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359631', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359663', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359695', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359727', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359759', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359791', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359823', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359855', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359887', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359919', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359951', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359983', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360015', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360047', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360079', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360111', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360143', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_358991', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357967', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357455', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357199', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357071', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357007', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_356975', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359215', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358159', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357615', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357327', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357167', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357103', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357039', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1496 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of psoriasis vulgaris? | In the context of psoriasis vulgaris, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis vulgaris%" OR LOWER(efo_term) LIKE "%psoriasis vulgaris%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057597', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058080', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058241', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058402', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058724', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058885', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059046', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059368', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059529', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059690', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059851', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060173', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060334', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060495', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060656', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060817', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060978', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061139', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061300', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061461', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061622', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061944', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062105', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062266', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062427', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062588', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062910', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063071', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063232', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063393', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063554', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063715', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063876', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064037', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064198', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064359', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064520', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064681', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064842', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065003', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065164', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065325', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065486', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065647', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065808', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065969', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066130', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066291', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066452', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066613', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066774', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067096', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067257', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067418', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067579', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067740', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067901', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068223', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068384', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068545', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068706', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068867', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069028', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069189', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069350', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069511', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069672', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069833', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069994', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070155', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070316', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070477', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070638', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070799', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070960', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071121', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071282', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071443', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071604', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071765', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071926', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072087', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072248', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072409', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066935', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061783', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059207', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057919', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057275', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056953', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056792', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068062', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062749', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060012', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058563', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057758', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057436', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057114', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.726 | Q34 | What are the names of the genes that are targeted by the drug Dabrafenib Mesylate in the treatment of cutaneous melanoma? | In the context of cutaneous melanoma, the drug Dabrafenib Mesylate targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cutaneous melanoma%" OR LOWER(efo_term) LIKE "%cutaneous melanoma%") AND (LOWER(drugName) LIKE "%dabrafenib mesylate%" OR LOWER(tradeNames_list) LIKE "%dabrafenib mesylate%" OR LOWER(syns_list) LIKE "%dabrafenib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752711', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752732', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752739', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752746', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752760', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752767', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752774', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752788', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752795', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752802', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752809', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752823', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752830', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752837', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752844', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752851', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752858', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752865', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752872', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752879', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752886', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752900', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752907', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752914', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752921', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752928', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752942', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752949', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752956', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752963', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752970', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752977', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752893', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752781', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752725', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752697', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752683', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752676', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752935', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752816', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752753', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752718', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752704', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752690', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.674 | Q34 | What are the names of the genes that are targeted by the drug Apremilast in the treatment of pustulosis palmaris et plantaris? | In the context of pustulosis palmaris et plantaris, the drug Apremilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pustulosis palmaris et plantaris%" OR LOWER(efo_term) LIKE "%pustulosis palmaris et plantaris%") AND (LOWER(drugName) LIKE "%apremilast%" OR LOWER(tradeNames_list) LIKE "%apremilast%" OR LOWER(syns_list) LIKE "%apremilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696935', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697019', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697047', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697075', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697131', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697159', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697187', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697243', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697271', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697299', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697327', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697383', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697411', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697439', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697467', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697495', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697523', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697551', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697579', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697607', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697635', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697691', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697719', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697747', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697775', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697803', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697859', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697887', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697915', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697943', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697971', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697999', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698027', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698055', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698083', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698111', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698139', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698167', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698195', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698223', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698251', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698279', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698307', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698335', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698363', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698391', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698419', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698447', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698475', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698503', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698531', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698587', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698615', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698643', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698671', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698699', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698727', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698783', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698811', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698839', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698867', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698895', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698923', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698951', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698979', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699007', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699035', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699063', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699091', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699119', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699147', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699175', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699203', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699231', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699259', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699287', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699315', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699343', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699371', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699399', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699427', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699455', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699483', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699511', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699539', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699567', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_698559', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697663', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697215', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696991', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696879', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696823', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696795', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698755', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697831', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697355', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697103', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696963', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696907', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696851', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'pustulosis palmaris et plantaris', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.32 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole Lauroxil in the treatment of autism? | In the context of autism, the drug Aripiprazole Lauroxil targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%autism%" OR LOWER(efo_term) LIKE "%autism%") AND (LOWER(drugName) LIKE "%aripiprazole lauroxil%" OR LOWER(tradeNames_list) LIKE "%aripiprazole lauroxil%" OR LOWER(syns_list) LIKE "%aripiprazole lauroxil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158027', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158045', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158051', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158057', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158069', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158075', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158081', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158093', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158099', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158105', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158111', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158123', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158129', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158135', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158141', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158147', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158153', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158159', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158165', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158171', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158177', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158189', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158195', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158201', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158207', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158213', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158225', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158231', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158237', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158243', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158249', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158255', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158261', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158267', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158273', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158279', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158285', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158291', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158297', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158303', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158309', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158315', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158321', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158327', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158333', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158339', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158345', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158351', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158357', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158363', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158369', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158381', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158387', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158393', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158399', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158405', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158411', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158423', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158429', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158435', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158441', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158447', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158453', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158459', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158465', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158471', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158477', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158483', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158489', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158495', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158501', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158507', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158513', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158519', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158525', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158531', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158537', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158543', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158549', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158555', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158561', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158567', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158573', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158579', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158585', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158591', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158375', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158183', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158087', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158039', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158015', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158003', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157997', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158417', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158219', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158117', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158063', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158033', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158021', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158009', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.906 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of Back pain? | In the context of Back pain, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%back pain%" OR LOWER(efo_term) LIKE "%back pain%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838161', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839108', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839149', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838862', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838076', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838297', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838534', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838370', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838944', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839354', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839518', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838616', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839641', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839682', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838739', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839026', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839067', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838493', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839559', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838042', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838246', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839313', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839436', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839395', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839477', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838127', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838110', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838059', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838178', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838212', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838195', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838263', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838903', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838821', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838780', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838144', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838452', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838280', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838229', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838698', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839600', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838657', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839272', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838093', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838575', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838985', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838411', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839190', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838329', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839231', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838482', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838523', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838974', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839015', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839056', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839097', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838564', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838933', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839138', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839179', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838605', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839220', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838318', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838359', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838646', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838687', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839302', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839384', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839425', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838728', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839466', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839507', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838769', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839548', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839343', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839589', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838400', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838810', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839630', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839671', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838851', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838441', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838892', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839261', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.959 | Q34 | What are the names of the genes that are targeted by the drug Mesalamine in the treatment of proctitis? | In the context of proctitis, the drug Mesalamine targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, peroxisome proliferator activated receptor gamma and arachidonate 5-lipoxygenase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%proctitis%" OR LOWER(efo_term) LIKE "%proctitis%") AND (LOWER(drugName) LIKE "%mesalamine%" OR LOWER(tradeNames_list) LIKE "%mesalamine%" OR LOWER(syns_list) LIKE "%mesalamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842715', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842766', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_842783', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_842800', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_842834', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_842851', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_842868', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_842885', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_842749', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842681', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842647', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842630', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842817', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_842732', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842698', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842664', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'syns_list': "['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.216 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of primary adrenal insufficiency? | In the context of primary adrenal insufficiency, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%primary adrenal insufficiency%" OR LOWER(efo_term) LIKE "%primary adrenal insufficiency%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218722', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219346', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219554', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219762', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220178', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220386', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220594', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220802', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219138', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218306', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217890', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217682', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219970', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218930', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218514', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218098', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.787 | Q34 | What are the names of the genes that are targeted by the drug Olaparib in the treatment of neoplasm? | In the context of neoplasm, the drug Olaparib targets the gene poly(ADP-ribose) polymerase 2, poly(ADP-ribose) polymerase 1 and poly(ADP-ribose) polymerase family member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%olaparib%" OR LOWER(tradeNames_list) LIKE "%olaparib%" OR LOWER(syns_list) LIKE "%olaparib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_795259', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795054', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795527', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795726', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796059', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796130', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796197', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795390', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795192', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795056', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795593', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795728', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795795', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795996', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795994', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796060', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796061', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796196', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796193', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796261', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796262', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795324', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795392', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795393', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795524', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795055', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795057', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795725', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795590', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795658', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795659', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795794', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795791', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795859', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795860', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796127', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795255', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795995', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795257', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796126', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795258', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796063', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796062', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796328', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796129', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796195', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796194', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796327', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796260', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796264', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796263', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795322', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795326', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795325', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795458', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795391', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795457', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795525', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795190', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795523', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795460', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795191', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795122', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795123', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795124', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795927', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795058', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795592', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795591', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795724', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795657', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795661', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795660', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795926', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795727', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795793', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795792', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795925', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795858', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795862', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795861', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796329', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795256', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795992', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795929', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796331', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796330', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795928', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795526', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795459', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795389', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795323', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795189', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795456', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795121', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795594', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795993', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796128', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795125', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795188', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.328 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of pulmonary tuberculosis? | In the context of pulmonary tuberculosis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary tuberculosis%" OR LOWER(efo_term) LIKE "%pulmonary tuberculosis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227784', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228639', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228924', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229209', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229779', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230064', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230349', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230919', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231204', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231489', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231774', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232344', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230634', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228354', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227214', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226644', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226359', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232059', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229494', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228069', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227499', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226929', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.564 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of Back pain? | In the context of Back pain, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%back pain%" OR LOWER(efo_term) LIKE "%back pain%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_640883', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637247', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639963', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637107', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637147', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638583', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637187', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637227', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639503', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637267', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642033', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640423', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636907', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_643413', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637007', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638353', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638468', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_643873', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637027', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638813', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638928', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637047', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639273', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639388', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_641458', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637067', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639848', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642378', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636927', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640193', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640308', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642608', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_640538', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640653', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640768', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_643758', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636947', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638238', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637387', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_643643', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637407', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_643528', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637427', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_644218', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637447', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638698', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637467', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_644103', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637487', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643988', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637507', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637527', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639158', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637547', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_641228', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637567', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_641113', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641803', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637607', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_639618', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637627', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641688', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637647', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641573', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637667', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_643068', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637687', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_640078', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637287', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642263', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637778', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642148', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637307', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_642953', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637893', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642493', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637327', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_642838', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_638008', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642723', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637347', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_644333', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_638123', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640998', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637367', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_644563', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644448', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_643183', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_641918', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_641343', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639043', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637207', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636967', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637587', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_639733', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636987', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_643298', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637167', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637087', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637127', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1280 | Q34 | What are the names of the genes that are targeted by the drug Entrectinib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Entrectinib targets the gene neurotrophic receptor tyrosine kinase 1, ALK receptor tyrosine kinase, neurotrophic receptor tyrosine kinase 2, neurotrophic receptor tyrosine kinase 3 and ROS proto-oncogene 1, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%entrectinib%" OR LOWER(tradeNames_list) LIKE "%entrectinib%" OR LOWER(syns_list) LIKE "%entrectinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_943002', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943023', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943030', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943037', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943051', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943058', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943065', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943079', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943086', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943093', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943100', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943114', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943121', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943128', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943135', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943142', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943149', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943156', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943163', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943170', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943177', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943191', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943198', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943205', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943212', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943219', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943233', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943240', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943247', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943254', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943261', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943268', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943275', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943282', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943289', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943296', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943303', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943310', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943317', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943324', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943331', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943338', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943345', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943352', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943359', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943366', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943373', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943380', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943387', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943394', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943401', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943415', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943422', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943429', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943436', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943443', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943450', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943464', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943471', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943478', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943485', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943492', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943499', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943506', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943513', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943520', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943527', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943534', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943541', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943548', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943555', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943562', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943569', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943576', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943583', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943590', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943597', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943604', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943611', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943618', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943625', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943632', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943639', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943646', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943653', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943660', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_943408', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943184', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943072', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943016', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942988', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942974', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942967', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943457', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_943226', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943107', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943044', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_943009', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942995', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942981', 'drugName': 'Entrectinib', 'tradeNames_list': "['Rozlytrek']", 'syns_list': "['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.705 | Q34 | What are the names of the genes that are targeted by the drug Imatinib Mesylate in the treatment of chronic myelogenous leukemia? | In the context of chronic myelogenous leukemia, the drug Imatinib Mesylate targets the gene ABL proto-oncogene 1, non-receptor tyrosine kinase, BCR activator of RhoGEF and GTPase, KIT proto-oncogene, receptor tyrosine kinase and platelet derived growth factor receptor beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic myelogenous leukemia%" OR LOWER(efo_term) LIKE "%chronic myelogenous leukemia%") AND (LOWER(drugName) LIKE "%imatinib mesylate%" OR LOWER(tradeNames_list) LIKE "%imatinib mesylate%" OR LOWER(syns_list) LIKE "%imatinib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_743542', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_743770', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_743846', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_743922', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_744074', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744150', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744226', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744378', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_744454', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_744530', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_744606', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_743694', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_743390', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_743238', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_743162', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744302', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_743998', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_743618', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_743466', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_743314', 'drugName': 'Imatinib Mesylate', 'tradeNames_list': "['Gleevec', 'Glivec', 'Imatinib mesylate']", 'syns_list': "['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medacImatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonateImatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571STI 571', 'STI-571', 'STI571']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.725 | Q34 | What are the names of the genes that are targeted by the drug Encorafenib in the treatment of metastatic melanoma? | In the context of metastatic melanoma, the drug Encorafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic melanoma%" OR LOWER(efo_term) LIKE "%metastatic melanoma%") AND (LOWER(drugName) LIKE "%encorafenib%" OR LOWER(tradeNames_list) LIKE "%encorafenib%" OR LOWER(syns_list) LIKE "%encorafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752309', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752351', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752365', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752379', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752407', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752421', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752435', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752463', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752477', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752491', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752505', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752533', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752547', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752561', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752575', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752589', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752603', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752617', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752631', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752645', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752659', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752673', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752449', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752337', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752281', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752253', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752239', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752519', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752393', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752323', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752295', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752267', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1213 | Q34 | What are the names of the genes that are targeted by the drug Propranolol Hydrochloride in the treatment of Wolff-Parkinson-White Syndrome? | In the context of Wolff-Parkinson-White Syndrome, the drug Propranolol Hydrochloride targets the gene adrenoceptor beta 2 and adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%wolff-parkinson-white syndrome%" OR LOWER(efo_term) LIKE "%wolff-parkinson-white syndrome%") AND (LOWER(drugName) LIKE "%propranolol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%propranolol hydrochloride%" OR LOWER(syns_list) LIKE "%propranolol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937044', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937021', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937090', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937067', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wolff-Parkinson-White Syndrome', 'efo_term': 'Wolff-Parkinson-White Syndrome', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.343 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of lateral epicondylitis? | In the context of lateral epicondylitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lateral epicondylitis%" OR LOWER(efo_term) LIKE "%lateral epicondylitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227799', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228654', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228939', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229224', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229794', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230079', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230364', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230934', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231219', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231504', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231789', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232359', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230649', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228369', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227229', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226659', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226374', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232074', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229509', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228084', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227514', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226944', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.634 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Sorafenib targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%sorafenib%" OR LOWER(tradeNames_list) LIKE "%sorafenib%" OR LOWER(syns_list) LIKE "%sorafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_683296', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683357', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683414', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683416', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683475', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683477', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683479', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683538', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683540', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683597', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683599', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683658', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683660', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683662', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683719', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683721', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683723', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683780', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683782', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683784', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683841', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683845', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683902', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683904', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683906', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683963', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683967', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684024', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684026', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684028', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684085', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684087', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684089', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684146', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684148', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684150', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684207', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684209', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684211', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684268', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684270', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684272', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684329', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684331', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684333', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684390', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684392', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684394', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684451', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684453', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684455', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684514', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684516', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684573', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684575', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684577', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684634', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684638', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684695', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684697', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684699', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684756', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684758', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684760', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684817', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684819', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684821', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684878', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684880', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684882', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684939', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684941', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684943', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685000', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685002', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685004', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685061', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685063', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685065', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685122', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685124', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685126', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685183', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685185', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685187', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685244', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684512', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683843', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683536', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683355', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683292', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683233', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683231', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684636', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683965', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683601', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683418', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683353', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683294', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683235', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.149 | Q34 | What are the names of the genes that are targeted by the drug Desonide in the treatment of eye inflammation? | In the context of eye inflammation, the drug Desonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye inflammation%" OR LOWER(efo_term) LIKE "%eye inflammation%") AND (LOWER(drugName) LIKE "%desonide%" OR LOWER(tradeNames_list) LIKE "%desonide%" OR LOWER(syns_list) LIKE "%desonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217430', 'drugName': 'Desonide', 'tradeNames_list': "['Desonate', 'Desonide', 'Desowen', 'Tridesilon', 'Verdeso']", 'syns_list': "['D-2083', 'D2083', 'Desonate', 'Desonide', 'NSC-759226']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217433', 'drugName': 'Desonide', 'tradeNames_list': "['Desonate', 'Desonide', 'Desowen', 'Tridesilon', 'Verdeso']", 'syns_list': "['D-2083', 'D2083', 'Desonate', 'Desonide', 'NSC-759226']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217436', 'drugName': 'Desonide', 'tradeNames_list': "['Desonate', 'Desonide', 'Desowen', 'Tridesilon', 'Verdeso']", 'syns_list': "['D-2083', 'D2083', 'Desonate', 'Desonide', 'NSC-759226']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1185 | Q34 | What are the names of the genes that are targeted by the drug Gilteritinib Fumarate in the treatment of myeloid leukemia? | In the context of myeloid leukemia, the drug Gilteritinib Fumarate targets the gene fms related receptor tyrosine kinase 3 and AXL receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myeloid leukemia%" OR LOWER(efo_term) LIKE "%myeloid leukemia%") AND (LOWER(drugName) LIKE "%gilteritinib fumarate%" OR LOWER(tradeNames_list) LIKE "%gilteritinib fumarate%" OR LOWER(syns_list) LIKE "%gilteritinib fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933934', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933937', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933938', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933939', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933936', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933932', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933930', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933929', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933940', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid', 'efo_term': 'myeloid leukemia', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933935', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933933', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933931', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'syns_list': "['ASP-2215 HEMIFUMARATE', 'ASP2215 hemifumarate', 'Gilteritinib fumarateGilteritinib hemifumarate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.362 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232532', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232613', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232640', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232667', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232721', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232748', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232775', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232829', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232856', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232883', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232910', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232964', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232991', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233018', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233045', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233072', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233099', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233126', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233153', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233180', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233207', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233261', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233288', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233315', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233342', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233369', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233423', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233450', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233477', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233504', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233531', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233558', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233585', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233612', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233639', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233666', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233693', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233720', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233747', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233774', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233801', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233828', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233855', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233882', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233909', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233936', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233963', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233990', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234017', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234044', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234071', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234125', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234152', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234179', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234206', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234233', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234260', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234314', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234341', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234368', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234395', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234422', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234449', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234476', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234503', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234530', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234557', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234584', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234611', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234638', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234665', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234692', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234719', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234746', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234773', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234800', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234827', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234854', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234881', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234908', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234935', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234962', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234989', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235016', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235043', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235070', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234098', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233234', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232802', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232586', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232478', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232424', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232397', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234287', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233396', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232937', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232694', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232559', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232505', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232451', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.85 | Q34 | What are the names of the genes that are targeted by the drug Levodopa in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Levodopa targets the gene dopamine receptor D3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%levodopa%" OR LOWER(tradeNames_list) LIKE "%levodopa%" OR LOWER(syns_list) LIKE "%levodopa%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_204986', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_205061', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_205086', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_205036', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204886', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204861', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204936', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_205011', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204961', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_204911', 'drugName': 'Levodopa', 'tradeNames_list': "['Bendopa', 'Brocadopa', 'Dopar', 'Inbrija', 'Larodopa']", 'syns_list': "['Bendopa', 'Cvt-301', 'Levodopa', 'Levodopum', 'NSC-118381', 'V-1512']", 'yearOfFirstApproval': 1970, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.49 | Q34 | What are the names of the genes that are targeted by the drug Paliperidone Palmitate in the treatment of schizophrenia? | In the context of schizophrenia, the drug Paliperidone Palmitate targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%paliperidone palmitate%" OR LOWER(tradeNames_list) LIKE "%paliperidone palmitate%" OR LOWER(syns_list) LIKE "%paliperidone palmitate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197439', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197445', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197447', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197449', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197453', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197455', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197457', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197461', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197463', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197465', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197467', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197471', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197473', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197475', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197477', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197479', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197481', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197483', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197485', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197487', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197489', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197493', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197495', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197497', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197499', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197501', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197505', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197507', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197509', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197511', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197513', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197515', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197517', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197519', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197521', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197523', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197525', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197527', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197529', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197531', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197533', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197535', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197537', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197539', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197541', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197543', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197545', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197547', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197549', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197551', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197553', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197555', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197491', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197459', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197443', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197435', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197431', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197429', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197503', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197469', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197451', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197441', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197437', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197433', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.472 | Q34 | What are the names of the genes that are targeted by the drug Oxymetazoline Hydrochloride in the treatment of ptosis? | In the context of ptosis, the drug Oxymetazoline Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ptosis%" OR LOWER(efo_term) LIKE "%ptosis%") AND (LOWER(drugName) LIKE "%oxymetazoline hydrochloride%" OR LOWER(tradeNames_list) LIKE "%oxymetazoline hydrochloride%" OR LOWER(syns_list) LIKE "%oxymetazoline hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_417245', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417275', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417285', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417295', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417315', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417325', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417335', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417355', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417365', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417375', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417385', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417405', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417415', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417425', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417435', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417445', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417455', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417465', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417475', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417485', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417495', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417515', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417525', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417535', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417545', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417555', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417575', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417585', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417595', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417605', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417615', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417625', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417635', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417645', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417655', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417665', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417675', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417685', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417695', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417705', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417715', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417725', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417735', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417745', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417755', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417765', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417775', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417785', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417795', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417805', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417815', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417835', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417845', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417855', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417865', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417875', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417885', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417905', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417915', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417925', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417935', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417945', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417955', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417965', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417975', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417985', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417995', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418005', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418015', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418025', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418035', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418045', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418055', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418065', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418075', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418085', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418095', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418105', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418115', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418125', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418135', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418145', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418155', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418165', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418175', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418185', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_417825', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417505', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417345', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417265', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417225', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417205', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417195', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417895', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417565', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417395', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417305', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417255', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417235', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417215', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.157 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218663', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219287', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219495', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219703', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220119', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220327', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220535', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220743', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219079', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218247', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217831', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217623', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219911', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218871', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218455', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218039', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.748 | Q34 | What are the names of the genes that are targeted by the drug Buprenorphine in the treatment of substance abuse? | In the context of substance abuse, the drug Buprenorphine targets the gene opioid receptor mu 1 and opioid receptor kappa 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%substance abuse%" OR LOWER(efo_term) LIKE "%substance abuse%") AND (LOWER(drugName) LIKE "%buprenorphine%" OR LOWER(tradeNames_list) LIKE "%buprenorphine%" OR LOWER(syns_list) LIKE "%buprenorphine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_764199', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764283', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764311', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764339', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764395', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764423', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764451', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764507', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764535', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764563', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764591', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764647', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764675', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764703', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764731', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764759', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764787', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764815', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764843', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764871', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764899', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764955', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764983', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765011', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765039', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765067', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765123', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765151', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765179', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765207', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765235', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765263', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765291', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765319', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765347', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765375', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765403', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765431', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765459', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765487', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765515', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765543', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765571', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765599', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765627', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765655', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765683', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765711', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765739', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765767', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765795', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765851', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765879', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765907', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765935', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765963', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765991', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766047', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766075', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766103', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766131', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766159', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766187', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766215', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766243', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766271', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766299', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766327', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766355', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766383', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766411', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766439', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766467', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766495', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766523', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766551', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765823', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764927', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764479', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764255', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764143', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764087', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764059', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766019', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765095', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764619', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764367', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764227', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764171', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764115', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1004 | Q34 | What are the names of the genes that are targeted by the drug Aclidinium Bromide in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Aclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%aclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%aclidinium bromide%" OR LOWER(syns_list) LIKE "%aclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857460', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857442', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857448', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857466', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857454', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1188 | Q34 | What are the names of the genes that are targeted by the drug Pacritinib Citrate in the treatment of polycythemia vera? | In the context of polycythemia vera, the drug Pacritinib Citrate targets the gene fms related receptor tyrosine kinase 3 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%polycythemia vera%" OR LOWER(efo_term) LIKE "%polycythemia vera%") AND (LOWER(drugName) LIKE "%pacritinib citrate%" OR LOWER(tradeNames_list) LIKE "%pacritinib citrate%" OR LOWER(syns_list) LIKE "%pacritinib citrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933971', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933977', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933979', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933981', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933975', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933967', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933963', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933961', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933983', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933973', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933969', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933965', 'drugName': 'Pacritinib Citrate', 'tradeNames_list': "['Vonjo']", 'syns_list': "['Pacritinib citrate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycythemia Vera', 'efo_term': 'polycythemia vera', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1387 | Q34 | What are the names of the genes that are targeted by the drug Brimonidine Tartrate in the treatment of glaucoma? | In the context of glaucoma, the drug Brimonidine Tartrate targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%glaucoma%" OR LOWER(efo_term) LIKE "%glaucoma%") AND (LOWER(drugName) LIKE "%brimonidine tartrate%" OR LOWER(tradeNames_list) LIKE "%brimonidine tartrate%" OR LOWER(syns_list) LIKE "%brimonidine tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034083', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034111', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034113', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034126', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034141', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034143', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034156', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034171', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034173', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034186', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034188', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034203', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034216', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034218', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034231', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034233', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034246', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034248', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034261', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034263', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034276', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034291', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034293', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034306', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034308', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034321', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034336', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034338', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034351', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034353', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034366', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034368', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034381', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034383', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034396', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034398', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034411', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034413', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034426', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034428', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034441', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034443', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034456', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034458', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034471', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034473', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034486', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034488', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034501', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034503', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034516', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034531', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034533', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034546', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034548', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034561', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034563', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034578', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034591', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034593', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034606', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034608', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034621', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034623', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034636', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034638', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034651', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034653', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034666', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034668', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034681', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034683', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034696', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034698', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034711', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034713', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034726', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034728', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034741', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034743', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034756', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034758', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034771', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034773', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034786', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034788', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034518', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034278', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034158', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034098', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034068', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034053', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034051', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034576', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034323', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034201', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034128', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034096', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034081', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034066', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1190 | Q34 | What are the names of the genes that are targeted by the drug Ripretinib in the treatment of neoplasm? | In the context of neoplasm, the drug Ripretinib targets the gene KIT proto-oncogene, receptor tyrosine kinase and platelet derived growth factor receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%ripretinib%" OR LOWER(tradeNames_list) LIKE "%ripretinib%" OR LOWER(syns_list) LIKE "%ripretinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933995', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934001', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934003', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934005', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934009', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934011', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934013', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934015', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_933999', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933991', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933987', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933985', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934007', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_933997', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933993', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933989', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1615 | Q34 | What are the names of the genes that are targeted by the drug Bivalirudin in the treatment of intermediate coronary syndrome? | In the context of intermediate coronary syndrome, the drug Bivalirudin targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%intermediate coronary syndrome%" OR LOWER(efo_term) LIKE "%intermediate coronary syndrome%") AND (LOWER(drugName) LIKE "%bivalirudin%" OR LOWER(tradeNames_list) LIKE "%bivalirudin%" OR LOWER(syns_list) LIKE "%bivalirudin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092329', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092312', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092363', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092346', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.504 | Q34 | What are the names of the genes that are targeted by the drug Amphetamine Sulfate in the treatment of narcolepsy-cataplexy syndrome? | In the context of narcolepsy-cataplexy syndrome, the drug Amphetamine Sulfate targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy-cataplexy syndrome%" OR LOWER(efo_term) LIKE "%narcolepsy-cataplexy syndrome%") AND (LOWER(drugName) LIKE "%amphetamine sulfate%" OR LOWER(tradeNames_list) LIKE "%amphetamine sulfate%" OR LOWER(syns_list) LIKE "%amphetamine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440698', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440707', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440710', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440713', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440719', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440722', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440725', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440731', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440734', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440737', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440740', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440746', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440749', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440752', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440755', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440758', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440761', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440764', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440767', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440770', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440728', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440704', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440692', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440686', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440683', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440743', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440716', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440701', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440695', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440689', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1879 | Q34 | What are the names of the genes that are targeted by the drug Cobicistat in the treatment of HIV-1 infection? | In the context of HIV-1 infection, the drug Cobicistat targets the gene cytochrome P450 family 3 subfamily A member 4, cytochrome P450 family 3 subfamily A member 5, cytochrome P450 family 3 subfamily A member 43 and cytochrome P450 family 3 subfamily A member 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hiv-1 infection%" OR LOWER(efo_term) LIKE "%hiv-1 infection%") AND (LOWER(drugName) LIKE "%cobicistat%" OR LOWER(tradeNames_list) LIKE "%cobicistat%" OR LOWER(syns_list) LIKE "%cobicistat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148831', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148864', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148875', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148886', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148908', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148919', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148930', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148941', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148853', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148809', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148787', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148776', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148897', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148842', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148820', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148798', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.181 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of contact dermatitis? | In the context of contact dermatitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%contact dermatitis%" OR LOWER(efo_term) LIKE "%contact dermatitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218687', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219311', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219519', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219727', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220143', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220351', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220559', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220767', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219103', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218271', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217855', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217647', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219935', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218895', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218479', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218063', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1036 | Q34 | What are the names of the genes that are targeted by the drug Duvelisib in the treatment of lymphoma? | In the context of lymphoma, the drug Duvelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lymphoma%" OR LOWER(efo_term) LIKE "%lymphoma%") AND (LOWER(drugName) LIKE "%duvelisib%" OR LOWER(tradeNames_list) LIKE "%duvelisib%" OR LOWER(syns_list) LIKE "%duvelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858820', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858860', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858838', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858756', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858760', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859116', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858896', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859020', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859140', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858940', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859078', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858976', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858856', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858996', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859256', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858780', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859036', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859000', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859258', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859076', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858900', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858818', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858918', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858796', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859158', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858936', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858836', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859236', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858840', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859060', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859200', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859238', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858980', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859198', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858858', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858798', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858776', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858880', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858740', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859098', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858876', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858758', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858998', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858800', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859038', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859260', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859240', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859276', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858898', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858978', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859040', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858736', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859080', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858916', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859136', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858920', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859120', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859196', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859056', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859156', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858938', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859180', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858778', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859178', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859176', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859278', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858956', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858958', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858960', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859220', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859018', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859280', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858878', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859138', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859118', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859058', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858816', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859218', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859216', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859016', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859160', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858738', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859096', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859100', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859071', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858991', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859031', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859091', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859048', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859088', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858868', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858871', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858731', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858791', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859111', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858888', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858891', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858808', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859108', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858811', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.991 | Q34 | What are the names of the genes that are targeted by the drug Nicotine Polacrilex in the treatment of nicotine dependence? | In the context of nicotine dependence, the drug Nicotine Polacrilex targets the gene cholinergic receptor nicotinic beta 2 subunit and cholinergic receptor nicotinic alpha 4 subunit. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nicotine dependence%" OR LOWER(efo_term) LIKE "%nicotine dependence%") AND (LOWER(drugName) LIKE "%nicotine polacrilex%" OR LOWER(tradeNames_list) LIKE "%nicotine polacrilex%" OR LOWER(syns_list) LIKE "%nicotine polacrilex%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857247', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857253', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857255', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857257', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857251', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857243', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857239', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857237', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857259', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857249', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857245', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_857241', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'syns_list': "['Nicotine polacrilex']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.760 | Q34 | What are the names of the genes that are targeted by the drug Hydrocodone Bitartrate in the treatment of pain? | In the context of pain, the drug Hydrocodone Bitartrate targets the gene opioid receptor mu 1, opioid receptor kappa 1 and opioid receptor delta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%hydrocodone bitartrate%" OR LOWER(tradeNames_list) LIKE "%hydrocodone bitartrate%" OR LOWER(syns_list) LIKE "%hydrocodone bitartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_776243', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775835', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776133', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775825', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776275', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776309', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775946', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775890', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776088', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775857', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776154', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775912', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776198', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776265', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775924', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776286', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775934', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776320', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775879', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776330', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775847', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776034', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776056', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775968', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776099', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775978', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775901', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776177', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775858', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776000', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776155', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776188', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776012', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776209', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776022', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776298', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775923', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776264', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775869', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776297', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776276', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776287', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775935', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776352', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776308', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776319', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775945', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776342', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775880', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776341', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776331', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775957', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776045', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776044', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776067', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775967', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776066', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776122', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776078', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776089', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775979', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776121', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776100', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776111', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775989', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776231', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775902', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776144', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776143', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776176', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776001', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776166', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776165', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776221', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776011', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776187', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775913', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776220', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776199', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776210', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776023', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776353', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776242', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776253', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776033', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776364', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776363', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776232', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776132', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776077', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776055', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775956', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775824', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775891', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776110', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775836', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_776254', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775846', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775990', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_775868', 'drugName': 'Hydrocodone Bitartrate', 'tradeNames_list': "['Dicodid', 'Hysingla', 'Hysingla er', 'Mercodinone', 'Vantrela erZohydro er']", 'syns_list': "['CEP-33237', 'Dihydrocodeinone bitartrate', 'HycodanHydrocodone bitartrate', 'Hydrocodone bitartrate ciiHydrocodone bitartrate hemipentahydrate', 'Hydrocodone tartrateVantrela', 'Zohydro']", 'yearOfFirstApproval': 1943, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.868 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of non-allergic rhinitis? | In the context of non-allergic rhinitis, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-allergic rhinitis%" OR LOWER(efo_term) LIKE "%non-allergic rhinitis%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834438', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834909', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835066', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835223', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835537', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835694', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835851', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836008', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834752', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834124', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833810', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833653', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835380', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834595', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834281', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833967', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.